DexCom, GE, SLB: Why Experts Rate These Stocks at Strong Buy
Wall Street gives these three diverse names Strong Buy recommendations with high potential upside.
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered daily
Kiplinger Today
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more delivered daily. Smart money moves start here.
Sent five days a week
Kiplinger A Step Ahead
Get practical help to make better financial decisions in your everyday life, from spending to savings on top deals.
Delivered daily
Kiplinger Closing Bell
Get today's biggest financial and investing headlines delivered to your inbox every day the U.S. stock market is open.
Sent twice a week
Kiplinger Adviser Intel
Financial pros across the country share best practices and fresh tactics to preserve and grow your wealth.
Delivered weekly
Kiplinger Tax Tips
Trim your federal and state tax bills with practical tax-planning and tax-cutting strategies.
Sent twice a week
Kiplinger Retirement Tips
Your twice-a-week guide to planning and enjoying a financially secure and richly rewarding retirement
Sent bimonthly.
Kiplinger Adviser Angle
Insights for advisers, wealth managers and other financial professionals.
Sent twice a week
Kiplinger Investing Weekly
Your twice-a-week roundup of promising stocks, funds, companies and industries you should consider, ones you should avoid, and why.
Sent weekly for six weeks
Kiplinger Invest for Retirement
Your step-by-step six-part series on how to invest for retirement, from devising a successful strategy to exactly which investments to choose.
When markets are trading near record levels the number of stocks getting Strong Buy consensus recommendations with high potential price upside tends to go down. But that doesn't mean there aren't select bang-the-table bargains to be found.
It's not a stock market, as the cliche goes, but a market of stocks.
True, the S&P 500 is up a whopping 30% on a price basis since its early April nadir and looks pricey by historical measures. But as an index weighted by market cap, much of this upside is driven by the S&P 500's biggest companies.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The top five — Nvidia (NVDA), Microsoft (MSFT), Apple (AAPL), Amazon.com (AMZN) and Meta Platforms (META) — collectively have a 28% weighting in the benchmark index.
However, the equal-weight version of the index, in which every component accounts for 2%, looks very different.
The equal-weight S&P 500 is up about 23% since the spring bottom, and it's considerably cheaper than its cap-weighted sibling. While the benchmark index trades at about 28 times weighted average earnings estimates, the equal-weight S&P 500 goes for less than 22.
Meanwhile, a better-than-expected second-quarter earnings season has the bull market alive and well.
"Nearly 60% of companies have raised their forward guidance for full-year earnings per share," writes Grant Engelbart, investment strategist at Carson Group, "something nearly unthinkable earlier this year when companies were withdrawing guidance completely in the wake of tariff uncertainty."
Given this supportive backdrop for equities, we decided to suss out some of Wall Street's favorite stocks to buy now — and to see what the bull cases on these names looked like.
DexCom
DexCom (DXCM) stock is a long-term market beater that's on sale right now, bulls say.
Shares in the maker of continuous glucose monitoring devices for diabetes patients are trailing the broader market by a painful 12 percentage points so far this year — but that just has them priced for outsize returns going forward.
A regulatory warning and concerns about reimbursement rates have pressured DXCM stock, but analysts say those overhangs are overdone.
"We are encouraged by accelerating trends and coverage expansion with meaningful top-line and margin drivers coming into view," writes Matthew Taylor, senior equity research analyst at Jefferies, who rates the stock at Buy. "We continue to be bullish on DXCM, seeing beat and raise quarters ahead."
Jefferies, which calls DXCM a Franchise Pick (one of its best ideas), has plenty of company on the Street. Of the 27 analysts covering DXCM surveyed by S&P Global Market Intelligence, 20 rate it at Strong Buy, three call it a Buy and four have it at Hold. That works out to a rare consensus recommendation of Strong Buy.
Meanwhile, analysts' average price target of $102.08 gives DXCM implied upside of about 34% in the next 12 months or so.
GE Aerospace
GE Aerospace (GE), which retained the classic GE ticker following the spinoff of GE Vernova (GEV) in 2024, has seen its shares soar as it returns gobs of cash to shareholders.
Bulls credit canny management and cost-savings initiatives, among other efforts, to boost results.
"GE Aerospace has been focusing on improving its supply chain by working closely with suppliers," notes Argus Research analyst Kristina Ruggeri, who rates shares at Buy. "These efforts have meaningfully improved the availability of components for GE, translating into higher sales and margins for the company."
As a result, the company was able to boost its dividend by nearly 30% earlier this year, all while buying back $4 billion in stock and counting. GE plans to repurchase $7 billion worth of its shares in 2025 after buying back more than $5 billion last year.
That's helped lift GE stock by nearly 65% for the year to date. Analysts see even more outsized upside ahead. Of the 17 analysts covering GE, 12 rate it at Strong Buy, three say Buy and two call it a Hold. That works out to a consensus recommendation of Strong Buy.
The Street's average price target of $273.01 gives the stock implied price upside of about 10% in the next year. The most bullish analysts, however, think the GE stock can gain more than 25%.
SLB
Bulls say SLB (SLB), the oilfield services giant formerly known as Schlumberger, is trading at a discount given concerns over a "wobbly pricing environment." That makes SLB — a company with "industry-leading margins" — a bargain at current levels.
True, North American revenue dipped sequentially last quarter, but the international segment showed growth. Additionally, the company's acquisition of ChampionX, which closed in July, should be strategically helpful in the short term, notes Stewart Glickman, energy equity analyst at CFRA Research, who rates the stock at Buy.
Then there's all the cash SLB is returning to shareholders. The company recently reaffirmed its plan to spend $4 billion on share repurchases and dividends in 2025, up from $3.27 billion in 2024.
With shares down about 6% so far this year, the yield on SLB's dividend stands at 3.3%. For comparison's sake, the yield on the S&P 500 stands at 1.2%.
"We believe that SLB shares are especially attractive at current prices and that the dividend is safe and sustainable in the current energy environment, despite weak macroeconomic trends," writes Bill Selesky of Argus Research, who rates shares at Buy.
Of the 29 analysts covering SLB, 18 call it a Strong Buy, seven say Buy and three have it Hold. Their average target price of $45.43 gives shares implied upside of about 29% in the next 12 months.
Related content
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.
A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.
Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.
In his current role at Kiplinger, Dan writes about markets and macroeconomics.
Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.
Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.
-
Quiz: Do You Know How to Avoid the "Medigap Trap?"Quiz Test your basic knowledge of the "Medigap Trap" in our quick quiz.
-
5 Top Tax-Efficient Mutual Funds for Smarter InvestingMutual funds are many things, but "tax-friendly" usually isn't one of them. These are the exceptions.
-
AI Sparks Existential Crisis for Software StocksThe Kiplinger Letter Fears that SaaS subscription software could be rendered obsolete by artificial intelligence make investors jittery.
-
5 Top Tax-Efficient Mutual Funds for Smarter InvestingMutual funds are many things, but "tax-friendly" usually isn't one of them. These are the exceptions.
-
Why Invest In Mutual Funds When ETFs Exist?Exchange-traded funds are cheaper, more tax-efficient and more flexible. But don't put mutual funds out to pasture quite yet.
-
Social Security Break-Even Math Is Helpful, But Don't Let It Dictate When You'll FileYour Social Security break-even age tells you how long you'd need to live for delaying to pay off, but shouldn't be the sole basis for deciding when to claim.
-
I'm an Opportunity Zone Pro: This Is How to Deliver Roth-Like Tax-Free Growth (Without Contribution Limits)Investors who combine Roth IRAs, the gold standard of tax-free savings, with qualified opportunity funds could enjoy decades of tax-free growth.
-
One of the Most Powerful Wealth-Building Moves a Woman Can Make: A Midcareer PivotIf it feels like you can't sustain what you're doing for the next 20 years, it's time for an honest look at what's draining you and what energizes you.
-
Stocks Make More Big Up and Down Moves: Stock Market TodayThe impact of revolutionary technology has replaced world-changing trade policy as the major variable for markets, with mixed results for sectors and stocks.
-
I'm a Wealth Adviser Obsessed With Mahjong: Here Are 8 Ways It Can Teach Us How to Manage Our MoneyThis increasingly popular Chinese game can teach us not only how to help manage our money but also how important it is to connect with other people.
-
Looking for a Financial Book That Won't Put Your Young Adult to Sleep? This One Makes 'Cents'"Wealth Your Way" by Cosmo DeStefano offers a highly accessible guide for young adults and their parents on building wealth through simple, consistent habits.